{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}]}],"title":"Absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"}]}],"title":"Minimal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"}]}],"title":"Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"title":"Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Severe"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"A 5-point scale was used for the Physician's global assessment on autoinflammatory disease activity (absent, minimal, mild, moderate and severe) and for the assessment of the following items:\n\n* skin disease (urticarial skin rash)\n* arthralgia\n* myalgia\n* headache/migraine\n* conjunctivitis\n* fatigue/malaise\n* other symptoms related to autoinflammatory syndrome\n* other symptoms not related to autoinflammatory syndrome","groups":[{"description":"ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.","id":"OG000","title":"ACZ885"},{"description":"Placebo subcutaneous injection every 8 weeks.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"32 weeks after study start","title":"Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part)","type":"SECONDARY","unitOfMeasure":"Participants"}